Abbvie Inc

NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024

ABBV Articles

The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and initiations for Thursday included AbbVie, Ally Financial, Anthem, Caterpillar, CVS Health, Deere, Oracle, PayPal, Rite Aid, Square, Uber Technologies and...
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The top analyst upgrades, downgrades and initiations for Wednesday included AbbVie, Camping World, Cleveland-Cliffs, Coupa Software, Dollar General, DuPont, Nike, Roku and StoneCo.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These five companies all pay at least a 6% dividend and offer a reasonable degree of safety. Even if a recovery in their share prices takes a while, the high dividends will make the wait much more...
The included AbbVie, Beyond Meat, Bio-Rad Laboratories, Dell Technologies, HP, Jumia Technologies, Nabriva Therapeutics, PG&E, Salesforce.com and Sarepta Therapeutics.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas, 10 tied mostly to retailing of apparel and accessories, and six are tied to pharmaceuticals and biotech.
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
The top analyst upgrades, downgrades and initiations on Wednesday included AbbVie, Archer Daniels Midland, ConocoPhillips, FedEx, Fox, Kinder Morgan, Lennar, Micron Technology, Slack Technologies and...
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.